Free tool
FAERS Monitor: Lumizyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125291 or its brand name (Lumizyme, Alglucosidase Alfa). Reports on generic versions are filed under their own applications.
Reports
2,436
Serious
921
38% of reports
Hospitalization
540
Death reported
118
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- inappropriate schedule of product administration219
- pyrexia179
- off label use153
- dyspnoea141
- malaise105
- fatigue100
- pneumonia100
- fall95
- drug specific antibody present89
- urticaria87
- infusion related reaction83
- rash83
- pain81
- weight decreased71
- asthenia70
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 24 |
| 2012 | 43 |
| 2013 | 153 |
| 2014 | 210 |
| 2015 | 181 |
| 2016 | 143 |
| 2017 | 148 |
| 2018 | 146 |
| 2019 | 182 |
| 2020 | 121 |
| 2021 | 225 |
| 2022 | 263 |
| 2023 | 210 |
| 2024 | 150 |
| 2025 | 130 |
| 2026 | 102 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,723 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug specific antibody presentSignal | 89 | 119.8 | 97.5 | 10,226 |
| infusion related reactionSignal | 83 | 10.8 | 8.8 | 732 |
| inappropriate schedule of product administrationSignal | 219 | 10.5 | 9.3 | 1,888 |
| urticariaSignal | 87 | 4.5 | 3.6 | 234 |
| pyrexiaSignal | 179 | 4.5 | 3.9 | 486 |
| pneumoniaSignal | 100 | 2.7 | 2.2 | 104 |
| fallSignal | 95 | 2.5 | 2.0 | 83 |
| weight decreasedSignal | 71 | 2.2 | 1.7 | 46 |
| dyspnoeaSignal | 141 | 2.2 | 1.8 | 88 |
| malaiseSignal | 105 | 2.1 | 1.7 | 58 |
| rash | 83 | 1.6 | 1.3 | 21 |
| asthenia | 70 | 1.6 | 1.3 | 16 |
| off label use | 153 | 1.5 | 1.3 | 27 |
| pain | 81 | 1.1 | 0.9 | 1 |
| fatigue | 100 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.